In patients with tumor PD-L1 < 1%, median PFS (95% CI) was 7.2 (2.9–19.3) months with nivolumab plus ipilimumab versus 4.5 (4.0–7.0) months with chemotherapy (HR 0.64; 95% CI, 0.32–1.28); 5-year PFS rate was 10% versus 0% (Fig. 2B). Here, CD274 is linked to neoplasm.